Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Arianna ZappaterraIvan CivettiniAnna Maria CafroLaura PezzettiSilvia PieriniMichela AnghilieriLaura BellioPaola BertazzoniGiovanni GrilloPeriana MingaMaria L PioltelliEmanuele RavanoMarianna SassoneClara V ViganòElisabetta B VolpatoCarlo Gambacorti-PasseriniSilvano RossiniRoberto CairoliRoberto CrocchioloPublished in: Blood transfusion = Trasfusione del sangue (2024)
Our findings underscore the impact of daratumumab-based treatment on CD34+ mobilization in a real-life, upfront plerixafor-free population of NDMM patients. Higher probability of requiring multiple apheresis occurred among daratumumab-treated patients. Interestingly, the observation that daratumumab might negatively impact BFU-E colony formation, independent of CD34+ cell count, offers novel biological perspectives. Appropriate strategies should be adopted by the Apheresis teams to mitigate these potential negative effects.